You are correct, even though it is understood that obesity can lead to other serious health conditions. One approach the Apis Bull is taking is to trial GLP-1 drugs as separate meds for treating other conditions like heart disease, kidney disease, etc. Unfortunately, creating a library of GLP-1 drugs costs significantly more than having a single one for treating the underlying problem.